Completed NA INTERVENTIONAL NCT00002215
A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive
Sponsor: Triangle Pharmaceuticals
Conditions
HIV Infections
Interventions
Emivirine Nelfinavir mesylate
Updated 1 time since 2024 Last updated: Jun 23, 2005
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A NA clinical study on HIV Infections, this trial is completed. The trial is conducted by Triangle Pharmaceuticals and has accumulated 1 data snapshot since 2026. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
1 version recorded Completed — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Triangle Pharmaceuticals
Data source: NIH AIDS Clinical Trials Information Service
For direct contact, visit the study record on ClinicalTrials.gov .